Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer

Green, Darrell ORCID: https://orcid.org/0000-0002-0217-3322, Eyre, Heather, Singh, Archana, Taylor, Jessica, Chu, Jason, Jeys, Lee, Sumathi, Vaiyapuri, Coonar, Aman, Rassl, Doris, Babur, Muhammad, Forster, Duncan, Alzabin, Saba, Ponthan, Frida, McMahon, Adam, Bigger, Brian, Reekie, Tristan, Kassiou, Michael, Williams, Kaye, Dalmay, Tamas ORCID: https://orcid.org/0000-0003-1492-5429, Fraser, William and Finegan, Katherine (2020) Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer. Oncogene, 39 (33). 5553–5569. ISSN 0950-9232

Preview	PDF (Accepted_Manuscript) - Accepted Version Download (277kB) | Preview
Preview	PDF (Published manuscript) - Published Version Available under License Creative Commons Attribution. Download (3MB) | Preview

Abstract

Metastasis is the leading cause of cancer related death. This multistage process involves contribution from both tumour cells and the tumour stroma to release metastatic cells into the circulation. Circulating tumour cells (CTCs) survive circulatory cytotoxicity, extravasate and colonise secondary sites effecting metastatic outcome. Reprogramming the transcriptomic landscape is a metastatic hallmark but detecting underlying master regulators that drive pathological gene expression is a key challenge, especially in childhood cancer. Here we used whole tumour plus single cell RNA sequencing in primary bone cancer and CTCs to perform weighted gene co-expression network analysis to systematically detect coordinated changes in metastatic transcript expression. This approach with comparisons applied to data collected from cell line models, clinical samples and xenograft mouse models revealed MAPK7/MMP9 signalling as a driver for primary bone cancer metastasis. RNAi knockdown of MAPK7 reduces proliferation, colony formation, migration, tumour growth, macrophage residency/polarisation and lung metastasis. Parallel to these observations were reduction of activated interleukins IL1B, IL6, IL8 plus mesenchymal markers VIM and VEGF in response to MAPK7 loss. Our results implicate a newly discovered, multidimensional MAPK7/MMP9 signalling hub in primary bone cancer metastasis that is clinically actionable.

Item Type:	Article
Uncontrolled Keywords:	molecular biology,genetics,cancer research,sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/1300/1312
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School Faculty of Science > School of Biological Sciences
UEA Research Groups:	Faculty of Science > Research Groups > Plant Sciences Faculty of Medicine and Health Sciences > Research Groups > Musculoskeletal Medicine Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Related URLs:	http://www.scopus.com/inward/record.url?...
Depositing User:	LivePure Connector
Date Deposited:	28 May 2020 00:20
Last Modified:	19 Oct 2023 02:41
URI:	https://ueaeprints.uea.ac.uk/id/eprint/75318
DOI:	10.1038/s41388-020-1379-0

Downloads

Actions (login required)

View Item